Daily Amino Acid Supplementation for People With Parkinson's Disease

Recruiting · NCT07115563 · Interventional (participants receive a specific treatment) · Lead sponsor: Cristina Colon-Semenza

View the official record on ClinicalTrials.gov →

Parkinson's disease

Interventions studied

Control (placebo)Targeted Amino Acid Supplement

What this trial is about

The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid supplement increase essential amino acids (nutritional status)? Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress? Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement? Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease. Participants will: Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.

Who can take part

Age range

50 Years to 90 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Eligibility criteria (as published)

Inclusionary Criteria: * Male and Females. * 50-80 Years. * Previous diagnosis of idiopathic Parkinson's Disease by patient report. * Use of dopamine replacement medication (e.g. levodopa) for at least 2 years. * On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months. Exclusionary criteria * Apparent cognitive impairment as determined by phone screening (Telephone Interview for Cognitive Status \<29). * Diagnosis of Parkinsonism or atypical Parkinson's Disease. * Prescription of Dopamine antagonist. * Any unstable medical condition. * Use of Deep Brain Stimulation. * Gastric or Bowel resection surgery. * Contraindications to blood draw.

Where it is running

2 locations listed across 1 US state.

UConn Health - Farmington, Connecticut, United States
University of Connecticut - Storrs, Connecticut, United States

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →